Published in Oncotarget on July 07, 2017
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood (2008) 4.10
Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem (2003) 3.30
Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov (2007) 3.14
Cancer immunoediting from immune surveillance to immune escape. Immunology (2007) 3.03
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem (2008) 2.44
Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol (2005) 2.34
When are "positive" clinical trials in oncology truly positive? J Natl Cancer Inst (2010) 2.09
Association of cell surface mucins with galectin-3 contributes to the ocular surface epithelial barrier. J Biol Chem (2009) 1.82
Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun (2007) 1.82
The CA 125 gene: a newly discovered extension of the glycosylated N-terminal domain doubles the size of this extracellular superstructure. Tumour Biol (2002) 1.44
The size of the synaptic cleft and distinct distributions of filamentous actin, ezrin, CD43, and CD45 at activating and inhibitory human NK cell immune synapses. J Immunol (2003) 1.39
Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer. Clin Cancer Res (2013) 1.30
Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA125. Gynecol Oncol (2005) 1.30
Tumor markers in metastatic breast cancer subtypes: frequency of elevation and correlation with outcome. Ann Oncol (2011) 1.20
Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125). Immunology (2007) 1.16
Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy. Lung Cancer (2009) 1.13
MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Mol Cancer (2014) 1.10
The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer. Ann Oncol (1990) 1.08
Characterization of the human folate receptor alpha via novel antibody-based probes. Oncotarget (2011) 1.06
MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells. Mol Cancer (2010) 1.06
Neutrophil CD64: a diagnostic marker for infection and sepsis. Clin Chem Lab Med (2009) 1.05
Fc-Receptor Interactions Regulate Both Cytotoxic and Immunomodulatory Therapeutic Antibody Effector Functions. Cancer Immunol Res (2015) 1.05
A metalloproteinase secreted by Streptococcus pneumoniae removes membrane mucin MUC16 from the epithelial glycocalyx barrier. PLoS One (2012) 0.95
Human antibodies for immunotherapy development generated via a human B cell hybridoma technology. Proc Natl Acad Sci U S A (2006) 0.94
Structural basis for binding of human IgG1 to its high-affinity human receptor FcγRI. Nat Commun (2015) 0.93
The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity. Cancer Biol Ther (2013) 0.92
Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer. Clin Cancer Res (2014) 0.92
The clinical correlates of serum CA125 in 169 patients with epithelial ovarian carcinoma. Br J Cancer (1989) 0.91
Ig Constant Region Effects on Variable Region Structure and Function. Front Microbiol (2016) 0.90
A critical review of the analytical approaches for circulating tumor biomarker kinetics during treatment. Ann Oncol (2014) 0.88
Follow-up with CA125 after primary therapy of advanced ovarian cancer: in favor of continuing to prescribe CA125 during follow-up. Ann Oncol (2011) 0.87
CA 125 in normal tissues and carcinomas of the uterine cervix, endometrium and Fallopian tube. II. Immunoradiometric determination in secretions, tissue extracts and serum. Arch Gynecol Obstet (1989) 0.83
Serum folate receptor alpha as a biomarker for ovarian cancer: Implications for diagnosis, prognosis and predicting its local tumor expression. Int J Cancer (2015) 0.81
Enhanced binding of antibodies generated during chronic HIV infection to mucus component MUC16. Mucosal Immunol (2016) 0.80
Assessment of sialic acid diversity in cancer- and non-cancer related CA125 antigen using sialic acid-binding Ig-like lectins (Siglecs). Dis Markers (2012) 0.80
The low affinity Fc receptor for IgG functions as an effective cytolytic receptor for self-specific CD8 T cells. J Immunol (2005) 0.80
PEGylation of bovine serum albumin using click chemistry for the application as drug carriers. Biotechnol Prog (2012) 0.77
Correlation of FCGRT genomic structure with serum immunoglobulin, albumin and farletuzumab pharmacokinetics in patients with first relapsed ovarian cancer. Genomics (2017) 0.76
[Relationship between serum levels and immunohistological tissue levels of CA 125 and CEA in epithelial ovarian cancers: its implications for tumor cell type specificity]. Nihon Sanka Fujinka Gakkai Zasshi (1986) 0.76